Express Scripts (ESRX) PT Set at $100.00 by Leerink Swann

Express Scripts (NASDAQ:ESRX) received a $100.00 target price from research analysts at Leerink Swann in a research note issued on Thursday. The brokerage currently has a “hold” rating on the stock. Leerink Swann’s target price points to a potential upside of 3.12% from the stock’s current price.

ESRX has been the topic of a number of other research reports. ValuEngine raised shares of Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, September 17th. Robert W. Baird cut shares of Express Scripts from an “outperform” rating to a “neutral” rating and set a $81.00 price target on the stock. in a research note on Friday, July 20th. BidaskClub raised shares of Express Scripts from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 12th. William Blair raised shares of Express Scripts from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 1st. Finally, Zacks Investment Research cut shares of Express Scripts from a “hold” rating to a “sell” rating in a research note on Monday, July 23rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $87.79.

Shares of NASDAQ ESRX opened at $96.97 on Thursday. The company has a market cap of $53.64 billion, a PE ratio of 13.66, a PEG ratio of 1.20 and a beta of 1.01. Express Scripts has a 12 month low of $59.17 and a 12 month high of $97.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.59 and a current ratio of 0.71.



Express Scripts (NASDAQ:ESRX) last released its quarterly earnings results on Wednesday, October 31st. The company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.01. Express Scripts had a net margin of 4.65% and a return on equity of 25.49%. The firm had revenue of $25.56 billion for the quarter, compared to analysts’ expectations of $25.11 billion. During the same quarter last year, the company earned $2.51 EPS. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, analysts forecast that Express Scripts will post 9.07 EPS for the current fiscal year.

In other Express Scripts news, insider Christine Houston sold 12,898 shares of Express Scripts stock in a transaction on Friday, August 10th. The shares were sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the sale, the insider now owns 110,908 shares of the company’s stock, valued at approximately $9,427,180. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.79% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. raised its holdings in shares of Express Scripts by 17.4% during the 1st quarter. Principal Financial Group Inc. now owns 969,252 shares of the company’s stock worth $66,956,000 after acquiring an additional 143,479 shares during the period. CenturyLink Investment Management Co purchased a new position in shares of Express Scripts during the 2nd quarter worth $1,741,000. Indiana Trust & Investment Management CO purchased a new position in shares of Express Scripts during the 2nd quarter worth $1,879,000. DnB Asset Management AS purchased a new position in shares of Express Scripts during the 2nd quarter worth $16,974,000. Finally, Burke & Herbert Bank & Trust Co. purchased a new position in shares of Express Scripts during the 2nd quarter worth $285,000. 84.74% of the stock is currently owned by institutional investors.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Featured Article: Institutional Investors

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply